Treventis Awarded $2.97M Grant from the U.S. Department of Defense
yahoo.com
finance
2022-10-18 14:05:00

Funds for Development of Its Anti-Tau Drug Against Neurodegenerative Diseases

BERNVILLE, Pa., Oct. 18, 2022 /PRNewswire/ -- Treventis Corporation, a privately held biotechnology company, announced today that their proposal to preclinically develop a small molecule anti-tau misfolding drug has been awarded funding totaling $2,977,166 by the Congressionally Directed Medical Research Programs (CDMRP), part of the DOD.

Treventis' proposal, "Development of a small molecule anti-misfolding drug for frontotemporal degeneration," was submitted in response to the Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program - Technology/Therapeutic Development Award (PRMRP-TTDA), which was solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.
